GeneDx Holdings Corp. (WGS)
NASDAQ: WGS · Real-Time Price · USD
137.47
+6.81 (5.21%)
At close: Oct 28, 2025, 4:00 PM EDT
138.00
+0.53 (0.39%)
After-hours: Oct 28, 2025, 7:58 PM EDT
GeneDx Holdings Revenue
GeneDx Holdings had revenue of $116.74M in the quarter ending September 30, 2025, with 51.86% growth. This brings the company's revenue in the last twelve months to $402.19M, up 50.50% year-over-year. In the year 2024, GeneDx Holdings had annual revenue of $305.45M with 50.79% growth.
Revenue (ttm)
$402.19M
Revenue Growth
+50.50%
P/S Ratio
9.68
Revenue / Employee
$402,190
Employees
1,000
Market Cap
3.97B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 305.45M | 102.88M | 50.79% |
| Dec 31, 2023 | 202.57M | -32.13M | -13.69% |
| Dec 31, 2022 | 234.69M | 22.50M | 10.60% |
| Dec 31, 2021 | 212.20M | 32.87M | 18.33% |
| Dec 31, 2020 | 179.32M | -16.85M | -8.59% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
WGS News
- 10 hours ago - GeneDx Holdings Corp. (WGS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 19 hours ago - GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights - Business Wire
- 1 day ago - GeneDx: A Moment Of Reckoning As Market Awaits Q3 Testing Growth - Seeking Alpha
- 1 day ago - GeneDx Holdings Corp. (NASDAQ: WGS) Investor Reminder: Schubert Jonckheer Investigating Possible False Claims - PRNewsWire
- 4 days ago - Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 6 days ago - GeneDx Showcases Leadership in Genomic Newborn Screening at ICoNS 2025 - Business Wire
- 8 days ago - GeneDx Granted FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ Testing - Business Wire
- 13 days ago - Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot - PRNewsWire